<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679846</url>
  </required_header>
  <id_info>
    <org_study_id>2014-852</org_study_id>
    <secondary_id>2014-A01460-47</secondary_id>
    <nct_id>NCT02679846</nct_id>
  </id_info>
  <brief_title>Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SAVE is a stratified cluster-randomised controlled, parallel group, open-label trial, with&#xD;
      Epileptic Monitoring Unit (EMU) as the units of randomisation and patients as the unit of&#xD;
      analysis.&#xD;
&#xD;
      The focus of research is the management of AntiEpileptic Drugs (AEDs) withdrawal during long&#xD;
      term Video EEG (VEEG) monitoring in patients with drug resistant seizures. This&#xD;
      non-standardised medical practice, which aims at promoting the occurrence of seizures during&#xD;
      the time limit of the monitoring period, exposes patients to significant risks which should&#xD;
      be minimised by harmonisation of practice and a standardised protocol of AEDs withdrawal.&#xD;
&#xD;
      SAVE will assess the impact of a standardised protocol of AEDs withdrawal during long-term&#xD;
      VEEG monitoring on the frequency of seizure-related serious adverse events occurring during&#xD;
      these monitorings and on the ability to obtain VEEG recording of seizures within appropriate&#xD;
      time limits.&#xD;
&#xD;
      10 of the 22 EMUs will be randomised to the group where the standardised protocol of AEDs&#xD;
      withdrawal will be used systematically, while the other ten EMUs will continue their current&#xD;
      non-standardised practice of AEDs withdrawal, and will serve as a control group.&#xD;
&#xD;
      The setting of the study will include a 6 months evaluation phase, prior to randomisation,&#xD;
      during which the organisational characteristics, baseline EMUs' activity, current management&#xD;
      of AEDs withdrawal, and rate of Serious Adverse Events (SAEs) of each participating center&#xD;
      will be evaluated.&#xD;
&#xD;
      The standardised study protocol of AEDs withdrawal has been defined on the basis of a&#xD;
      systematic review of all relevant publications in the field.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
    <description>Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring, defined as the occurrence of one or more of the following events:&#xD;
Convulsive or non-convulsive status epilepticus&#xD;
4-hour seizure cluster (≥ 3 seizures / 4 hours)&#xD;
secondarily generalised seizure unusual for the patient (≤ 1/year)&#xD;
vertebral compression&#xD;
other fracture (including broken tooth)&#xD;
post-ictal psychosis&#xD;
post-ictal aspiration pneumonia&#xD;
cardio-respiratory arrest&#xD;
Any other seizure-related serious injury or adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop each of the above seizure-related SAEs during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop SAEs unrelated to the occurrence of a seizure, during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop adverse events, including serious and non-serious adverse events, during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between onset of monitoring and VEEG recording of the first seizure (in hours)</measure>
    <time_frame>from date of inclusion until the first seizure (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom at least one seizure will be recorded during the VEEG monitoring</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom the duration of VEEG monitoring will extend beyond its initially scheduled time limits</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of VEEG</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1567</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Standardized protocol of AEDs withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Centers will continue their current practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized protocol</intervention_name>
    <description>The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients</description>
    <arm_group_label>Standardized protocol of AEDs withdrawal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female suffering from drug-resistant epilepsy&#xD;
&#xD;
          -  Age ≥ 6 years old&#xD;
&#xD;
          -  Inpatient in one of the participating EMUs for recording seizure during long-term VEEG&#xD;
             monitoring (≥ 48 hours)&#xD;
&#xD;
          -  Patient who gave its written informed consent to participate to the study, or for&#xD;
             children, whose minimum one of parents had given its written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 6 years old&#xD;
&#xD;
          -  Inpatient in one of the participating EMUs for performing short-term VEEG monitoring&#xD;
             (&lt;48 hours)&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain RHEIMS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital R. Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital HFME</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital P. Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital R. Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital G. de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ch. Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>St Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Teppe</name>
      <address>
        <city>Tain</city>
        <zip>26602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>withdrawal of antiepileptic drugs</keyword>
  <keyword>monitoring VEEG</keyword>
  <keyword>safety</keyword>
  <keyword>adverse event</keyword>
  <keyword>standardized protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

